NS1652 is primarily researched for its potential therapeutic applications in treating cystic fibrosis. It functions as a chloride channel activator, which helps in restoring the normal flow of chloride ions across cell membranes. This action is crucial in alleviating the symptoms of cystic fibrosis, as the disease is characterized by impaired chloride transport. Additionally, NS1652 has shown promise in reducing inflammation and mucus buildup in the airways, improving lung function in preclinical studies. Its ability to modulate ion channels also makes it a candidate for research in other conditions involving ion transport abnormalities, such as certain types of kidney disorders. Further studies are ongoing to explore its full therapeutic potential and safety profile.